Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.

FDA adds 53 entries to the list of standards it will recognize for device pre-market submissions, and grants de novo approval for two device types. Civil money penalty amounts increase on inflation adjustment. The Center for Biologics Evaluation and Research searches for a review branch chief. More regulatory news.